Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

Dardano et al. (2012): The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with Iodine-131 + (131I treatment)
Upadhyaya et al. (2017): Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differential thyroid cancer: A randomized-controlled trial + (131I treatment)

Kadhim et al. (2021): Effect of Ginger Tea on Chemotherapy-Induced Nausea and Vomiting among Patients Attending the Oncology Teaching Hospital, Baghdad 2020 + (?)
Williams et al. (1996): Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity + (?)
Montazeri et al. (2013): Iranian Red Crescent Medical JournalEﬀect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients. + (?)
Sharp et al. (2009): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer + (?)
Iovino et al. (2018): High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naive lymphocytes and prevents TTV reactivation + (After stem cell transplantation)
Najafizade et al. (2013): Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: A randomized placebo-controlled trial + (Al the patients were treated with daily fractions of 180 to 200 Gy lasting from 5to 9weeks, for atotal dose of 6000 to 7000 cGy. The radiation fields were the same for al patients, and the tongue was always included.)
Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 + (All patients chemotherapy (Intervention/ p … All patients chemotherapy (Intervention/ placebo arm): Doxorubicin/cyclophosphamide 35 (33 %)/ 37 (36 %)Doxorubicin/cyclophosphamide/taxane 56 (52 %)/ 54 (52 %)Other anthracycline-based chemo 6 (6 %)/ 0 (0 %)Other nonanthracycline-based chemo 10 (9 %)/ 12 (12 %)Adjuvant Tamoxifen therapy planned (intervention/ placebo arm):Yes 55 (51 %)/ 56 (54 %)No 52 (49 %)/ 47 (46 %) (51 %)/ 56 (54 %) No 52 (49 %)/ 47 (46 %))
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer + (All patients got axillary dissection due to mammary cancer and receive now combined decongestive therapy (CDT) for the lymphoedema.)
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers + (All patients received 50 to 70 Gy telecobalt therapy using a standard daily radiation dose of 2 Gy in 25-35 fractions over a period of 6-7 weeks)
Dale et al. (2001): Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects + (All patients received 50-60 Gy of external beam radiation in 20-30 fractions over a period of 5 weeks, followed by intra-cavitary brachytherapy at a dose of 20–30 Gy using a BARC applicator.)
Sangthawan et al. (2015): Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy + (All patients treated with Cobalt 60 or 6 MV photon treatment machines, the daily fractionation was 2 Gy in 5 weekly fractions)
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation + (Allogenic bone marrow transplantation "All … Allogenic bone marrow transplantation"All the patients received cyclophosphamide 60 mg/kg for 2 days (on day -2 and -3, total dose 120 mg/kg) and busulfan 4 mg/kg for 4 days (on day -7 until day -4, total dose 16 mg/kg) as the conditioning regimen. In order to prevent GVHD, cyclosporine A 3 mg/kg/day i.v. was administered 3 days before BMT until the 5th day after BMT. Thereafter, oral cyclosporine A at 12.5 mg/kg/day was begun. Moreover, methotrexate 10 mg/m²/day i.v. for one day (+1) and 6 mg/m²/day for 3 days (+3, +6, and +11) was administered. Established GVHD was treated with a combination of intravenous methyl prednisolone and then oral prednisolone. All the patients received granulocyte colony stimulating factor 300 mg/day i.v. until their absolute neutrophil count returned to 1000 cells/mL for 3 consecutive days." to 1000 cells/mL for 3 consecutive days.")
Rastelli et al. (2011): Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial + (Anastrozole)
Inglis et al. (2020): Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT + (Androgen deprivation therapy)
Zalat et al. (2020): Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy + (Anthracycline-chemotherapy, chemotherapy regime: AC: Adriamycin + cyclophosphamide, FAC: 5-flourouracil + Adriamycin +cyclophosphamide, CHOP: Cyclophosphamide + Adriamycin + Oncovin +Prednisone)
Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia + (Aromatase inhibitor therapy)
Kraft et al. (2012): L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial + (At entry 88% of patients in the placebo and 92% of patients in the L-Carnitine group received chemotherapy.)
Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial + (Autologous peripheral blood hematopoietic stem cell transplantation)
Stendell-Hollis et al. (2010): Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors + (Breast cancer survivors; completed primary … Breast cancer survivors; completed primary treatment(s) for invasive, early stage breast cancer at least 12 months prior and no more than 10 years prior; received chemotherapy (neo-adjuvant or adjuvant with any medically-prescribed agent/regime) for treatmentlly-prescribed agent/regime) for treatment)
Ribeiro et al. (2017): Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer + (CAPOX (capecitabine + oxaliplatin) schedule; capecitabine; 5-fluorouracil and folinic acid)
Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study + (Carboplatin-paclitaxel chemotherapy Types of chemotherapy, n (%) neoadjuvant: 4 (8.5), adjuvant: 43 (91.5))
Hoopfer et al. (2015): Three-arm randomized phase III trial: Quality aloe and placebo cream versus powder as skin treatment during breast cancer radiation therapy + (Chemotherapy before radiotherapy per arm … Chemotherapy before radiotherapy per armPowder arm: No = 47 (59.5%); Yes = 32 (40.5%)Aloe arm: No = 31 (38.3%); Yes = 50 (61.7%)Placebo arm: No = 36 (46.8%); Yes = 41 (53.3%)Surgery per arm: Powder arm: Mastectomy = 32 (40.5%); Segmental resection = 47 (59.5%)Aloe arm: Mastectomy = 34 (42%); Segmental resection = 47 (58%)Placebo arm: Mastectomy = 23 (29.9%); Segmental resection = 54 (70.1%) (29.9%); Segmental resection = 54 (70.1%))
Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment + (Chemotherapy or specific cancer therapy: 210 patients, hormone therapy only: 46 patients.)
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) + (Chemotherapy patients (received chemotherapy in the 4 weeks before baseline and who intended to continue chemotherapy during the study), per arm: THC = 52% Cannabis extract = 47% Placebo = 52%)
Heggie et al. (2002): A phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue + (Chemotherapy per arm (n): Aloe vera arm: yes = 24; no = 83 Placebo arm: yes = 24; no = 77)
Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer + (Chemotherapy regimen: CAPOX (capecitabine + oxaliplatin), Capecitabine or 5-fluorouracil + folinic acid)
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy + (Chemotherapy regimens (n intervention vs. … Chemotherapy regimens (n intervention vs. placebo arm):- AC, i.e. doxorubicin60 mg/m2 +cyclophosphamid 600 mg/m2 (41 vs. 44)- CAF, i.e. cyclophosphamide 500mg/m2 + doxorubicin 50mg/ m2 + 5-Fluorouracil 500mg/m2 (19 vs. 18)- TAC, i.e. docetaxel 75mg/m2 + doxorubicin 50mg/m2 + cyclophosphamide 500mg/m2 (15 vs. 13)up> + doxorubicin 50mg/m2 + cyclophosphamide 500mg/m2 (15 vs. 13))
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial + (Chemotherapy treatment by a regimen including cyclophosphamide, doxorubicin, dacarbazine, gemcitabine, methotrexate, and 5-fluorouracil)
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer + (Chemotherapy with adjuvant anthracycline (chemotherapy protocols: anthracycline, cyclophosphamide, doxorubicin, and 5-ﬂuorouracil), no significant differences between arms in chemotherapy characteristics (p > 0.05))
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy + (Chemotherapy with capecitabine Capecitabine alone (n = 43) Capecitabine + oxaliplatin (n = 24) Capecitabine + lapatinib (n = 5) Capecitabine + trastuzumab (n = 3) Capecitabine + cetuximab (n = 2))
Olsen et al. (2001): The effect of aloe vera gel/mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy + (Chemotherapy: Aloe arm: Yes = 28%, No = 72% Control arm: Yes = 26%, No = 74% Cumulative dose was dichotomized into ≤2,700 cGy or >2,700 cGy.)
Lissoni et al. (2009): A Randomized Study of Chemotherapy versus Biochemotherapy with Chemotherapy plus Aloe arborescens in Patients with Metastatic Cancer + (Chemotherapy: Non-small cell lung cancer … Chemotherapy: Non-small cell lung cancer: Chemotherapy consisted of cisplatin (CDDP) plus etoposide (VP16) or weekly vinorelbine (VNR)Small cell lung cancer: Chemotherapy consisted of cisplatin (CDDP) plus etoposide (VP16)Colorectal cancer: low-dose oxaliplatin (OXA) plus 5-fluorouracil (5-FU)Gastric cancer: weekly 5-fluorouracil Pancreatic adenocarcinoma: weekly gemcitabine (GEM)c adenocarcinoma: weekly gemcitabine (GEM))
Stephenson et al. (2017): Partner-delivered reflexology: Effects on cancer pain and anxiety. + (Chemptherapy/Radiation therapy/OP (at least 6 weeks before or after surgery))
Dias et al. (2015): The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study + (Cisplatin)
Fahimi et al. (2011): Evaluating the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens + (Cisplatin chemotherapy regimens, n (%) * … Cisplatin chemotherapy regimens, n (%) * Cisplatin + Etoposide 7 (19%)* Cisplatin + Gemcitabine 7 (19%)* Cisplatin + Docetaxel 11 (31%)* Cisplatin + Vinorelbine 4 (11%)* Cisplatin + Cyclophosphamide + Doxorubicin 4 (11%)* Cisplatin + Paclitaxel + Doxorubicin 1 (3%)* Cisplatin + 5-FU + Docetaxel 1 (3%)* Cisplatin + Pemetrexed 1 (3%)el 1 (3%) * Cisplatin + Pemetrexed 1 (3%))
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results + (Cisplatin-based chemotherapy)
Li et al. (2018): Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial + (Cisplatin-based chemotherapy (few patients with carboplatin or oxaliplatin))
Pace et al. (2010): Vitamin E neuroprotection for cisplatin neuropathy + (Cisplatin-based chemotherapy, cisplatin was administered in combination regimens on the basis of the specific tumor site)
Pace et al. (2003): Neuroprotective Effect of Vitamin E Supplementation in Patient Treated With Cisplatin Chemotherapy + (Cisplatin-based chemotherapy; Cisplatin w … Cisplatin-based chemotherapy;Cisplatin was administered in combination regimens based on the specific tumor site as follows: Lung and urethral cancer:cisplatin 75 mg/m² on day 1 and gemcitabine 1,000 mg/m² on day 1 and day 8 every 3 weeks; ovarian cancer: cisplatin 75 mg/m² and endoxan 600 mg/m² on day 1 every 3 weeks; head and neck cancer: cisplatin 100 mg/m² on day 1 and fluorouracil 1,000 mg/m² on day 1 to 4 every 3 to 4 weeks; ethmoidal cancer: cisplatin 25 mg/m² and etoposide 80 mg/m² on day 1 to 3 every 3 weeks; gastric cancer: PELF regimen (cisplatin 40 mg/m² and epirubicin 30 mg/m² on days 1 and 5 plus fluorouracil 300 mg/m² and folinic acid 100 mg/m² on days 1 to 4 every 3 weeks); testicular cancer: PEB regimen (cisplatin 20 mg/m² and etoposide 100 mg/m² on days 1 to 5 plus bleomycin 30 mg on days 2, 9, and 16 every 3 weeks) 30 mg on days 2, 9, and 16 every 3 weeks))
Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients + (Cisplatin-chemotherapy)
Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial + (Cisplatin-chemotherapy)